MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

UMI-77

CAS No. : 518303-20-3

MCE 国际站：UMI-77

产品活性：UMI-77是一种选择性的 Mcl-1 抑制剂，对 Mcl-1 具有高亲和力 (IC₅₀= 0.31 μM)。UMI-77 结到 Mcl-1 的 BH3 结合沟， K_i 值为 490 nM，比作用于 Bcl-2 家族其他成员的选择性高。

研究领域：Apoptosis

作用靶点：Bcl-2 Family

In Vitro: Competitive binding curve of UMI-77 against Mcl-1 is obtained by FP based binding assay using fluorescent labeled Bid BH3 peptide with an IC₅₀ of 1.87±0.22 μM. UMI-77 potently inhibits the cell growth of BxPC-3 and Panc-1 cell lines with IC₅₀ values of 3.4 μM and 4.4 μM respectively, and shows 3 to 5 times less potency in inhibition of the cell growth of two other tested cell lines MiaPaCa-2 (12.5 μM) and AsPC-1 (16.1 μM). The cell growth inhibition potency of UMI-77 correlates with the highest expression of Mcl-1 and Bak, and lowest expression of Bcl-xL in the sensitive cell lines, BxPC-3 and Panc-1. Capan-2 cells are showing similar sensitivity to UMI-77 (IC₅₀ of 5.5 μM) as BxPC-3 and Panc-1, although has low Mcl-1 levels^[1].

In Vivo: UMI-77 exhibits moderate metabolic stability with a half-life of 45 minutes.The maximum tolerated dose (MTD) of UMI-77 in SCID mice is determined. Administered 60 mg/kg i.v. for 5 consecutive days per week for two weeks does not cause any loss in the animal weight and there is no obvious sign of toxicity during the course of the treatment. Increasing the dose to 80 mg/kg show severe animal weight loss (>20%), therefore 60 mg/kg is used as a therapeutic dose for the in vivo efficacy studies. Daily treatment with UMI-77 for 5 consecutive days a week for two weeks results in statistically significant tumor growth inhibition by 65% and 56% in comparison with the controls in day 19 (p<0.0001) and day 22 (p<0.003) respectively^[1].

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Highly Selective Inhibitors Library  |  8α-Tigloyloxyhirsutinolide 13-O-acetate  |  F1324  |  Pyridoclax  |  Lobaplatin  |  Bcl-2-IN-10  |  Bim BH3, Peptide IV TFA  |  Amantadine-d₆  |  PROTAC Bcl-xL ligand-1  |  Anticancer agent 64  |  Bcl-2-IN-2  |  BPA-B9  |  Bcl-2-IN-8  |  PUMA BH3 TFA  |  Amantadine  |  MCL-1/BCL-2-IN-2  |  STAT3-IN-13  |  Murizatoclax  |  (E)-Ferulic acid  |  Lometrexol  |  Oxychlororaphine  |  BRD4 Inhibitor-15  |  Bim-IN-1  |  (S)-Gossypol (acetic acid)  |  S65487 sulfate  |  Pelcitoclax  |  Lobetyol  |  Carteolol  |  Antitumor agent-55  |  BT2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。